2.39
+0.07(+3.02%)
Currency In USD
| Previous Close | 2.32 |
| Open | 2.33 |
| Day High | 2.4 |
| Day Low | 2.31 |
| 52-Week High | 8 |
| 52-Week Low | 1.05 |
| Volume | 88,444 |
| Average Volume | 720,058 |
| Market Cap | 75.42M |
| PE | -1.13 |
| EPS | -2.12 |
| Moving Average 50 Days | 2.2 |
| Moving Average 200 Days | 1.85 |
| Change | 0.07 |
If you invested $1000 in Acrivon Therapeutics, Inc. Common Stock (ACRV) since IPO date, it would be worth $143.63 as of December 25, 2025 at a share price of $2.39. Whereas If you bought $1000 worth of Acrivon Therapeutics, Inc. Common Stock (ACRV) shares 2 years ago, it would be worth $478 as of December 25, 2025 at a share price of $2.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
GlobeNewswire Inc.
Dec 17, 2025 2:34 PM GMT
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gen
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
GlobeNewswire Inc.
Dec 17, 2025 12:30 PM GMT
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gener
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
GlobeNewswire Inc.
Dec 17, 2025 12:30 PM GMT
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Gen